Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs

Reuters

Oct 08, 2025

Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs

Zenas BioPharma Inc. (Nasdaq: ZBIO) has announced a private placement financing, raising approximately $120 million in gross proceeds. The company has entered into a securities purchase agreement to issue about 6.3 million shares of common stock to institutional and accredited investors at $19.00 per share, and to certain directors and officers at $20.85 per share. Jefferies and Evercore ISI acted as exclusive placement agents for the transaction, which attracted participation from both new and existing investors, including mutual funds and healthcare-focused funds. The proceeds are expected to support Zenas's operating expenses and capital requirements into the fourth quarter of 2026, and potentially into the first quarter of 2027 if a milestone payment from Royalty Pharma is received.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542044-en) on October 08, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573946780"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573946780\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573946780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573946780","market":"us","top_or_hot":-1,"title":"Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZBIO\">Zenas BioPharma Inc.</a> (Nasdaq: ZBIO) has announced a private placement financing, raising approximately $120 million in gross proceeds. The company has entered into a securities purchase agreement to issue about 6.3 million shares of common stock to institutional and accredited investors at $19.00 per share, and to certain directors and officers at $20.85 per share. Jefferies and <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI acted as exclusive placement agents for the transaction, which attracted participation from both new and existing investors, including mutual funds and healthcare-focused funds. The proceeds are expected to support Zenas's operating expenses and capital requirements into the fourth quarter of 2026, and potentially into the first quarter of 2027 if a milestone payment from Royalty Pharma is received.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542044-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZBIO\">Zenas BioPharma Inc.</a> (Nasdaq: ZBIO) has announced a private placement financing, raising approximately $120 million in gross proceeds. The company has entered into a securities purchase agreement to issue about 6.3 million shares of common stock to institutional and accredited investors at $19.00 per share, and to certain directors and officers at $20.85 per share. Jefferies and <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI acted as exclusive placement agents for the transaction, which attracted participation from both new and existing investors, including mutual funds and healthcare-focused funds. The proceeds are expected to support Zenas's operating expenses and capital requirements into the fourth quarter of 2026, and potentially into the first quarter of 2027 if a milestone payment from Royalty Pharma is received.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542044-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL95qJGM:1","article_id":"2573946780","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573946780","pubTimestamp":1759914018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zenas BioPharma Inc.  has announced a private placement financing, raising approximately $120 million in gross proceeds. The company has entered into a securities purchase agreement to issue about 6.3 million shares of common stock to institutional and accredited investors at $19.00 per share, and to certain directors and officers at $20.85 per share. Jefferies and Evercore ISI acted as exclusive placement agents for the transaction, which attracted participation from both new and existing investors, including mutual funds and healthcare-focused funds. The proceeds are expected to support Zenas's operating expenses and capital requirements into the fourth quarter of 2026, and potentially into the first quarter of 2027 if a milestone payment from Royalty Pharma is received.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","ZBIO":"Zenas BioPharma Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4007":"制药","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4127":"投资银行业与经纪业","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","RPRX":"Royalty Pharma plc","EVR":"Evercore"},"translate_title":"Zenas BioPharma宣布私募1.2亿美元以支持全球扩张和开发计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVR":0.9,"NDAQ":0.9,"RPRX":0.9,"ZBIO":0.9},"content_text":"Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs\n    \n\nZenas BioPharma Inc. (Nasdaq: ZBIO) has announced a private placement financing, raising approximately $120 million in gross proceeds. The company has entered into a securities purchase agreement to issue about 6.3 million shares of common stock to institutional and accredited investors at $19.00 per share, and to certain directors and officers at $20.85 per share. Jefferies and Evercore ISI acted as exclusive placement agents for the transaction, which attracted participation from both new and existing investors, including mutual funds and healthcare-focused funds. The proceeds are expected to support Zenas's operating expenses and capital requirements into the fourth quarter of 2026, and potentially into the first quarter of 2027 if a milestone payment from Royalty Pharma is received.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542044-en) on October 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}